BD first one fourth revenues boost 2.5 percent to $1 start here .888 billion BD , a respected global medical technology business, today reported quarterly revenues of $1.december 31 888 billion for the first fiscal quarter ended, 2011, representing a rise of 2.5 % from the prior-year period, or 2.4 % on a foreign currency-neutral basis. Forlenza, LEADER President and Officer. We will continue steadily to drive efficiency through the entire Firm and we remain focused on delivering value to your customers and shareholders.21, weighed against $1.35 in the prior-year period, representing a 10.4 % reduce.
Andrew Finn, Executive Vice President, Item Development at BDSI. We think that such something could have significant potential. Granisetron is referred to as a selective 5HT-3 receptor antagonist, which will be the most used treatments for preventing nausea and vomiting related broadly to radiation and chemotherapy. Product sales of 5HT-3 antagonists exceeded $1.7 billion in 2008. In line with the outcome of the debate with FDA, Phase 3 development could occur as soon as the start of 2011. BEMA Granisetron will be the third BEMA item to enter clinical advancement and follows the recent FDA acceptance of the first item to utilize the BEMA drug delivery technology, ONSOLIS , for the treating breakthrough discomfort in opioid tolerant individuals with cancer.